Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2584-2589

  Marr, Kieren A ^a,c   Lyons, Christopher N ^d   Rustad, Tiger ^c   Bowden, Raleigh A ^a,b,c   White, Theodore C ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMPHOTERICIN B; DNA; ERGOSTEROL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MESSENGER RNA; METHYLTRANSFERASE; STEROL;

ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; DNA SEQUENCE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOUTHERN BLOTTING; STEROL SYNTHESIS;

EID: 0031687814     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2584     Document Type: Article

References (35)

1. Albertson, G. D., M. Niimi, R. D. Cannon, and H. F. Jenkinson. 1996. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance. Antimicrob. Agents Chemother. 40:2835-2841.
2. Baily, G. G., F. M. Perry, D. W. Denning, and B. K. Mandal. 1994. Fluconazole-resistant candidosis in an HIV cohort. AIDS 8:787-792.
3. Barrett-Bee, K. J., A. C. Lane, and R. W. Turner. 1986. The mode of antifungal action of tolnaftate. J. Med. Vet. Mycol. 24:155-160.
4. Calvet, H. M., M. R. Yeaman, and S. G. Filler. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother. 41:535-539.
5. Galgiani, J., M. Bartlett, M. Espinel-Ingroff, R. Fromtling, M. Pfaller, and M. Rinaldi. 1992. Reference method for broth dilution antifungal susceptibility testing of yeasts. Proposed standard, vol. 12. National Committee for Clinical Laboratory Standards, Villanova, Pa.
6. Goodman, J. L., D. J. Winston, R. A. Greenfield, P. H. Chandrasekar, B. Fox, H. Kaizer, R. K. Shadduck, T. C. Shea, P. Stiff, D. J. Friedman, W. G. Powderly, J. L. Silber, H. Horowitz, A. Lichtin, S. N. Wolff, S. F. Mangan, S. M. Silver, D. Weisdorf, W. G. Ho, G. Gilbert, and D. Buell. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. 326:845-851.
7. Hoffman, C. S., and F. Winston. 1987. A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene 57:267-272.
8. Kelly, S. L., D. C. Lamb, D. E. Kelly, J. Loeffler, and H. Einsele. 1996. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348:1523-1524.
9. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, H. Hebart, U. Schumacher, and H. Einsele. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta(5,6)-desaturation. FEBS Lett. 400:80-82.
10. Lai, M. H., and D. R. Kirsch. 1989. Nucleotide sequence of cytochrome P450 L1A1 (lanosterol 14 alpha-demethylase) from Candida albicans. Nucleic Acids Res. 17:804.
11. Maenza, J. R., J. C. Keruly, R. D. Moore, R. E. Chaisson, W. G. Merz, and J. E. Gallant. 1996. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J. Infect. Dis. 173:219-225.
12. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
13. Marr, K. A., T. C. White, J. A. H. vanBurik, and R. A. Bowden. 1997. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis. 25:908-910.
14. Millon, L., A. Manteaux, G. Reboux, C. Drobacheff, M. Monod, T. Barale, and Y. Michel-Briand. 1994. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. J. Clin. Microbiol. 32:1115-1118.
15. Miyazaki, Y., A. Geber, T. Parkinson, C. Hitchcock, and J. E. Bennett. 1997. Complementation of Δ5,6-desaturase gene did not restore fluconazole susceptibility in Candida albicans Darlington strain, abstr. F-81, p. 274. In Abstracts of the 97th General Meeting of the American Society for Microbiology. American Society for Microbiology, Washington, D.C.
16. Mori, T., M. Matsumura, Y. Kanamaru, S. Miyano, T. Hishikawa, S. Irie, K. Oshimi, T. Saikawa, and T. Oguri. 1997. Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to agents during therapy. Clin. Infect. Dis. 25:2470-2471.
17. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
18. Pfaller, M. A., J. Rhine-Chalberg, S. W. Redding, J. Smith, G. Farinacci, A. W. Fothergill, and M. G. Rinaldi. 1994. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J. Clin. Microbiol. 32:59-64.
19. Powderly, W. G., K. Robinson, and E. J. Keath. 1992. Molecular typing of Candida albicans isolated from oral lesions of HIV-infected individuals. AIDS 6:81-84.
20. Prasad, R., W. P. De, A. Goffeau, and E. Balzi. 1995. Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals. Curr. Genet. 27:320-329.
21. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
22. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology (Reading) 143:405-416.
23. Sanglard, D., K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
24. Schmid, J., Y. P. Tay, L. Wan, M. Carr, D. Parr, and W. McKinney. 1995. Evidence for nosocomial transmission of Candida albicans obtained by Ca3 fingerprinting. J. Clin. Microbiol. 33:1223-1230.
25. Schmitt, M. E., T. A. Brown, and B. L. Trumpower. 1990. A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucleic Acids Res. 18:3091-3092.
26. Slavin, M. A., B. Osborne, R. Adams, M. J. Levenstein, H. G. Schoch, A. R. Feldman, J. D. Meyers, and R. A. Bowden. 1995. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis. 171: 1545-1552.
27. USPHS/IDSA Prevention of Opportunistic Infection Working Group. 1997. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with HIV: disease-specific recommendations. Clin. Infect. Dis. 25(Suppl. 3):S313-335.
28. Warnock, D. W., J. Burke, N. J. Cope, E. M. Johnson, N. A. von Fraunhofer, and E. W. Williams. 1988. Fluconazole resistance in Candida glabrata. Lancet ii:1310. (Letter.)
29. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
30. White, T. C. 1997. The presence of an R467K. amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14α demethylase in Candida albicans. Antimicrob. Agents Chemother. 41:1488-1494.
31. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
32. White, T. C., M. A. Pfaller, R. G. Rinaldi, J. Smith, and S. W. Redding. 1997. Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. 3(Suppl. 1):S102-S109.
33. Wingard, J. R. 1995. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. 20:115-125.
34. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl, J. Med. 325:1274-1277.
35. Wingard, J. R., W. G. Merz, M. G. Rinaldi, C. B. Miller, J. E. Karp, and R. Saral. 1993. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob. Agents Chemother. 37:1847-1849.